EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment
The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved…
June 19, 2019 - 3 minutes
AstraZeneca
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
April 9, 2018 - 4 minutes
Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment
Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody…
March 5, 2018 - 2 minutes
Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine
Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with…
February 28, 2018 - 3 minutes
AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development
AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and…
February 26, 2018 - 2 minutes
FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s
The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck…
February 21, 2018 - 2 minutes
The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead
The UK big pharma company's Lynparza will be for women with advanced breast cancer that…
January 15, 2018 - 3 minutes
AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed…
November 2, 2017 - 2 minutes
Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene
The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca…
October 20, 2017 - 2 minutes
Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis
Though the psoriasis market is teeming with effective products, companies have developed ways to devise…
October 17, 2017 - 7 minutes
UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster
UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months…
September 11, 2017 - 2 minutes
Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success
Circassia has positive Phase III results from its respiratory pipeline, great news for the company…
September 7, 2017 - 2 minutes
